Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

BACKGROUND: This study was conducted to evaluate the feasibility of long-term adalimumab (ADA) discontinuation after achievement of low disease activity (LDA) in Japanese patients with early rheumatoid arthritis (RA) and to identify predictors of LDA maintenance. METHODS: In the HOPEFUL-1 study, pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Yamanaka, Hisashi, Ishiguro, Naoki, Miyasaka, Nobuyuki, Kawana, Katsuyoshi, Kimura, Junko, Agata, Naoki, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348900/
https://www.ncbi.nlm.nih.gov/pubmed/28288682
http://dx.doi.org/10.1186/s13075-017-1264-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348900/
https://www.ncbi.nlm.nih.gov/pubmed/28288682
http://dx.doi.org/10.1186/s13075-017-1264-6

Ejemplares similares